Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Interventions in Obesity & Diabetes

Antidiabetic Treatments for Diabetes with Liver Cirrhosis

Submission: February 03, 2020Published: February 11, 2020

DOI: 10.31031/IOD.2020.03.000566

ISSN : 2578-0263
Volume3 Issue3

Abstract

Diabetes is associated with about 30% of liver cirrhosis and affects prognosis, carcinogenesis, and the onset of complications. In cirrhosis, fasting normal and postprandial hyperglycemia are often present, and evaluation by glucose tolerance test or continuous blood glucose measurement is also considered. Although no treatment strategy has been established, if renal function is maintained, metformin will be the first choice, but for renal dysfunction cases and metformin ineffective cases, insulin will be indicated. Although the efficacy and safety of incretin-related drugs and sodium-glucose cotransporter 2 inhibitors have not been established, they can be expected to be effective in cases with obesity. On the viewpoint of preventing sarcopenia and hepatocarcinogenesis, antidiabetic drugs should be selected. Exogenous insulin should be indicated for patients with Child C grade. This review discusses antidiabetic treatments for diabetes with liver cirrhosis.

Keywords:Metformin; Insulin; Incretin; Sodium-glucose cotransporter 2; Glucagon like peptide 1

Abbreviations:GA: Glycated Albumin; CLD: Chronic Liver Disease; HCC: Hepatocellular Carcinoma; CGMS: Continuous Glucose Monitoring System; FGM: Flash Glucose Monitoring; NASH: Nonalcoholic Steatohepatitis; αGI: Alpha Glucosidase Inhibitor; SGLT2: Sodium-Glucose Cotransporter 2; DPP-4: Dipeptidyl Peptidase-4

Get access to the full text of this article